Literature DB >> 363250

Multimodal immunotherapy of primary gastrointestinal tumors in rats. 1. Histologic correlation.

B R Bansal, J Mobini, S C Bansal.   

Abstract

The effect of multimodal immunotherapy was studied in rats bearing primary gastrointestinal tumors induced by 1,2-dimethylhydrazine dihydrochloride. Multimodal immune manipulation consisted of combinations of splenectomy, C. parvum, unblocking serum, unblocked lymphoid cells, and levamisole. Such immunologic intervention resulted in significant inhibition of tumor growth, and their metastasis. Ten of 10 untreated rats, 8 of 8 rats treated with splenectomy alone and 10 of 10 rats treated with normal rabbit serum died of progressive tumor growth. None of the rats treated with combinations of splenectomy, unblocking serum, unblocked lymphoid cells, C. parvum and levamisole succumbed to progressive tumor growth during the observation period. The histologic evidence of tumor destruction was obtained in 18 of 22 tumors in rats of groups receiving multimodal immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 363250     DOI: 10.1002/1097-0142(197811)42:5<2079::aid-cncr2820420502>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Effects of immunostimulation with OK432, coenzyme Q10, or levamisole on dimethylhydrazine-induced colonic carcinogenesis in rats.

Authors:  H Suzuki; J Yamamoto; Y Iwata; K Matsumoto; K Iriyama
Journal:  Jpn J Surg       Date:  1986-03

2.  Chemoprevention of development of colonic adenomatosis and carcinomatosis with 5-fluorouracil and ftorafur on animal model.

Authors:  T Narisawa; M Sato; M Tani; T Takahashi
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

3.  Clinical and in vivo response following surgery or surgery plus adjuvant chemotherapy or immunotherapy for colorectal carcinoma in a rat model.

Authors:  A K House; M A Maley
Journal:  J R Soc Med       Date:  1983-10       Impact factor: 18.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.